Aditxt (ADTX) Stock Price, News & Analysis

Company Overview

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Key Stats

• Today's Range: $0.12 to $0.12
• 50-Day Range: $0.13 to $0.40
• 52-Week Range: $0.12 to $218.00
• Volume: 18.53 million shs
• Average Volume: 61.09 million shs
• Market Capitalization: $1.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aditxt Stock Analysis - MarketRank™

Aditxt scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aditxt.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Aditxt has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.15% of the float of Aditxt has been sold short.

Short Interest Ratio / Days to Cover

Aditxt has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aditxt has recently increased by 1,070.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aditxt does not currently pay a dividend.

Dividend Growth

Aditxt does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.15% of the float of Aditxt has been sold short.

Short Interest Ratio / Days to Cover

Aditxt has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aditxt has recently increased by 1,070.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: -0.45

News Sentiment

Aditxt has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aditxt this week, compared to 1 article on an average week.

Search Interest

19 people have searched for ADTX on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aditxt insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.72% of the stock of Aditxt is held by insiders.

Percentage Held by Institutions

Only 15.54% of the stock of Aditxt is held by institutions.

ADTX Stock Analysis - Frequently Asked Questions

How have ADTX shares performed this year?

Aditxt's stock was trading at $0.1898 on January 1st, 2025. Since then, ADTX stock has decreased by 35.7% and is now trading at $0.1220.
View the best growth stocks for 2025 here.

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) issued its earnings results on Wednesday, August, 11th. The company reported ($33,600.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4,000.00) by $29,600.00.

When did Aditxt's stock split?

Shares of Aditxt reverse split on Wednesday, October 2nd 2024. The 1-40 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Aditxt?

Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aditxt investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Plug Power (PLUG), SNDL (SNDL), AMC Entertainment (AMC) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/11/2021
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADTX
• CUSIP: N/A
• CIK: 1726711
• Web: www.aditxt.com
• Phone: 650-870-1200
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-32,380,000.00
• Net Margins: N/A
• Pretax Margin: -30,525.09%
• Return on Equity: -439.07%
• Return on Assets: -122.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $212,107.00
• Price / Sales: 8.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2,687.49 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 14,234,000
• Free Float: 13,989,000
• Market Cap: $1.74 million
• Optionable: No Data
• Beta: 1.26